Literature DB >> 25575344

The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics.

Ernst R Berndt1, Robert S Gibbons2, Anton Kolotilin3, Anna Levine Taub4.   

Abstract

We present two new findings based on annual antipsychotic US prescribing data from IMS Health on 2867 psychiatrists who wrote 50 or more prescriptions in 2007. First, many of these psychiatrists have prescription patterns that are statistically significantly different than random draws from national market shares for prescriptions by psychiatrists. For example, many have prescription patterns that are significantly more concentrated than such draws. Second, among psychiatrists who are the most concentrated, different prescribers often concentrate on distinct drugs. Motivated by these two findings, we then construct a model of physician learning-by-doing that fits these facts and generates two further predictions: both concentration (on one or a few drugs) and deviation (from the prescription patterns of others) should be smaller for high-volume physicians. We find empirical support for these predictions. Furthermore, our model outperforms an alternative theory concerning detailing by pharmaceutical representatives.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antipsychotic prescriptions; Pharmaceutical concentration; Physician learning

Mesh:

Substances:

Year:  2014        PMID: 25575344     DOI: 10.1016/j.jhealeco.2014.11.003

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  6 in total

1.  We need an operational framework for heterogeneity in psychiatric research

Authors:  Abraham Nunes; Thomas Trappenberg; Martin Alda
Journal:  J Psychiatry Neurosci       Date:  2020-01-01       Impact factor: 6.186

2.  Patient, Physician and Organizational Influences on Variation in Antipsychotic Prescribing Behavior.

Authors:  Yan Tang; Chung-Chou H Chang; Judith R Lave; Walid F Gellad; Haiden A Huskamp; Julie M Donohue
Journal:  J Ment Health Policy Econ       Date:  2016-03

3.  Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia.

Authors:  Martin Andersen; Anurag Pant
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2022-04-27       Impact factor: 2.039

4.  Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany.

Authors:  Katharina E Blankart; Friederike Arndt
Journal:  Int J Environ Res Public Health       Date:  2020-06-09       Impact factor: 3.390

Review 5.  Functional Neuroimaging in Psychiatry-Aiding in Diagnosis and Guiding Treatment. What the American Psychiatric Association Does Not Know.

Authors:  Theodore A Henderson; Muriel J van Lierop; Mary McLean; John Michael Uszler; John F Thornton; Yin-Hui Siow; Dan G Pavel; Joe Cardaci; Phil Cohen
Journal:  Front Psychiatry       Date:  2020-04-15       Impact factor: 4.157

Review 6.  The definition and measurement of heterogeneity.

Authors:  Abraham Nunes; Thomas Trappenberg; Martin Alda
Journal:  Transl Psychiatry       Date:  2020-08-24       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.